Feb 23, 2021
Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up
Feb 18, 2021
Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021
Feb 11, 2021
Agenda for Targovax's Capital Markets Day 18 February 2021
Feb 10, 2021
Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
Jan 06, 2021
Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore
Dec 15, 2020
Targovax ASA: Save the date - Capital Markets Day 2021
Dec 01, 2020
Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
Nov 05, 2020
Targovax ASA: third quarter 2020 results
Oct 13, 2020
Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
Oct 12, 2020
Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
Jun 04, 2020
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
May 06, 2020
Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO
Apr 30, 2020
Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer
Apr 22, 2020
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Mar 03, 2020
Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma
Jan 21, 2020
Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
Jan 08, 2020
Updated Press Release: Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China
Nov 11, 2019
Presentation of ONCOS-102 Melanoma Data at SITC Annual Meeting
Nov 07, 2019
Targovax ASA: Third Quarter 2019 Results
Jul 08, 2019
Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma